A Case of Ticagrelor Resistance
Ticagrelor is a directly acting cyclopentyltriazolo-pyrimidine which does not require conversion into an active metabolite. It inhibits the P2Y12 receptors on platelets reversibly. Unlike clopidogrel and prasugrel, resistance to ticagrelor is rarely reported. Various mechanisms have been proposed fo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2021-07-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/2719 |
| id |
doaj-6c9c9b5e7e9842ce84011b43228117e6 |
|---|---|
| record_format |
Article |
| spelling |
doaj-6c9c9b5e7e9842ce84011b43228117e62021-09-03T07:48:23ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-07-0110.12890/2021_0027192335A Case of Ticagrelor ResistanceJahanzeb Malik0Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi, Punjab, PakistanTicagrelor is a directly acting cyclopentyltriazolo-pyrimidine which does not require conversion into an active metabolite. It inhibits the P2Y12 receptors on platelets reversibly. Unlike clopidogrel and prasugrel, resistance to ticagrelor is rarely reported. Various mechanisms have been proposed for this resistance. The case of a 62-year-old man with diabetes who had undergone index percutaneous coronary intervention (PCI) 22 days previously is described. The patient presented to us with stent thrombosis. His primary PCI was successfully carried out with a drug-eluting stent. He showed resistance to ticagrelor on thromboelastography platelet mapping. He responded well to prasugrel (another P2Y12 inhibitor) in combination with aspirin.https://www.ejcrim.com/index.php/EJCRIM/article/view/2719ticagrelorcoronary artery diseasestent thrombosisdual anti-platelet therapy |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Jahanzeb Malik |
| spellingShingle |
Jahanzeb Malik A Case of Ticagrelor Resistance European Journal of Case Reports in Internal Medicine ticagrelor coronary artery disease stent thrombosis dual anti-platelet therapy |
| author_facet |
Jahanzeb Malik |
| author_sort |
Jahanzeb Malik |
| title |
A Case of Ticagrelor Resistance |
| title_short |
A Case of Ticagrelor Resistance |
| title_full |
A Case of Ticagrelor Resistance |
| title_fullStr |
A Case of Ticagrelor Resistance |
| title_full_unstemmed |
A Case of Ticagrelor Resistance |
| title_sort |
case of ticagrelor resistance |
| publisher |
SMC MEDIA SRL |
| series |
European Journal of Case Reports in Internal Medicine |
| issn |
2284-2594 |
| publishDate |
2021-07-01 |
| description |
Ticagrelor is a directly acting cyclopentyltriazolo-pyrimidine which does not require conversion into an active metabolite. It inhibits the P2Y12 receptors on platelets reversibly. Unlike clopidogrel and prasugrel, resistance to ticagrelor is rarely reported. Various mechanisms have been proposed for this resistance. The case of a 62-year-old man with diabetes who had undergone index percutaneous coronary intervention (PCI) 22 days previously is described. The patient presented to us with stent thrombosis. His primary PCI was successfully carried out with a drug-eluting stent. He showed resistance to ticagrelor on thromboelastography platelet mapping. He responded well to prasugrel (another P2Y12 inhibitor) in combination with aspirin. |
| topic |
ticagrelor coronary artery disease stent thrombosis dual anti-platelet therapy |
| url |
https://www.ejcrim.com/index.php/EJCRIM/article/view/2719 |
| work_keys_str_mv |
AT jahanzebmalik acaseofticagrelorresistance AT jahanzebmalik caseofticagrelorresistance |
| _version_ |
1717817585472372736 |